Invetx, founded with the mission to revolutionize animal health through biopharmaceutical innovation, focuses on developing protein-based therapeutics for veterinary use. The company aims to leverage human biotechnology advancements to create a premier platform for animal health solutions. Invetx collaborates with leading biotechnology firms, major investors, and a network of industry experts to develop a portfolio of therapies and technologies that address significant health issues in animals.
Notable figures affiliated with Invetx include Dr. Marcus Remmers, a partner at Novo Holdings and an influential leader in the animal health industry, who serves on the company's Board of Directors. Key achievements include the development of a half-life extension technology platform for canine and feline monoclonal antibody treatments, significantly enhancing their duration of effect. Invetx's impact is underscored by its commitment to addressing chronic conditions like osteoarthritis in pets, aiming to improve the quality of life for animals globally.
